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Introduction
The nervous system is a complex network in our body that is responsible for actions,
reflexes, and even sensations. The nervous system is divided into two parts: the central nervous
system (CNS) and the peripheral nervous system (PNS). The CNS consists of the brain and
spinal cord. This part of the nervous system is the process center of the body.1 With the brain
being part of the CNS, many common nervous system disorders are due to a defect in the central
nervous system and the functions of this organ. These disorders include mental health problems,
degenerative diseases, seizures, infections, and other possible genetic diseases.2 Many of these
diseases are common in society and constantly researched. Even though these diseases are
common, treatment accessibility and effects on people of minority groups are overlooked
compared to the focus on majority groups. For drug development for these diseases to advance in
the right directions, it is important to include minority groups in the discussion.

History of Drug Development:
Drug development goes back thousands of years with the use of natural extracts, but the
search for new drugs importance increased in the twentieth century. According to UC Irvine
School of Pharmacy and Pharmaceutical Sciences, in 1900, one-third of all deaths in the United
States were from either pneumonia, tuberculosis, or diarrhea. Today, these causes of death are
rare because they are either preventable or treatable with medication. With the development of

more drugs the chance of dying from these three causes was 1 in 11 in 1940 and then 1 in 25 by
2000.3
Drug development in this age must go through many steps to reach market and be
considered safe to use on the public. According to the U.S. Food and Drug Administration
(FDA), there are five steps in the drug development process. Step one consists of research that
occurs in the laboratory. Typically, this starts when there are new insights on a given disease or
set of molecular compounds. This leads researchers to find possible beneficial effects of
molecular compounds against certain diseases and leads to the design of a product in hopes of
working against diseases. Discovery also includes further research on already existing treatments
in the market. As seen with many diseases and the variability of the human body, treatments
don’t work for everyone and diseases are ever-evolving, which is why the research and
treatments must be continuously ever-evolving, also. After the discovery, research is put into the
potential benefits and interactions of the treatment and the form and its administration.
The next step in drug development is known as preclinical research. This is to get a better
understanding of the toxicity of the treatment and whether the benefits outweigh the harm. This
research is normally conducted in a lab on animal subjects to understand the effects of the
treatment. These studies are conducted either in vitro or in vivo, in vitro meaning performed in a
test tube, culture dish, or outside of a living organism and in vivo meaning the test is conducted
in a living organism.
After preclinical research, clinical research must be conducted to ensure that the drug is
safe to use. The clinical research is to study the drug’s safety and shouldn’t be in place of other
studies conducted to answers questions about the drug’s safety. Once a drug reaches this step in
the process, clinical trials are designed that follow a certain protocol that determines selection

criteria, dosage of the drug, etc. This leads to many clinical research phase studies that can take
up to several years. In America, this process requires approval from the FDA and a FDA review
team is assigned to the study.
In the next phase, the FDA must review the drug to ensure it is effective. At this point,
there is evidence that this drug works on the certain disease or disorder. The drug has been
proven to not only be effective, but also safe on the test subjects, which includes both animals
and humans. The FDA carefully looks through all the submitted data and goes forward with their
decision to approve or not approve the drug. If the drug is approved, the drug can be patented
and placed for marketing. The FDA continues to monitor the drug’s safety even after the drug is
placed on the market. FDA monitoring is to ensure the drug remains safe and effective since it is
impossible to know the full works of the drug before it becomes available on the market and to
the public.4
The development of drugs for central nervous system diseases continues to be a challenge
even with the many advancements in technology. Many of the diseases we associate with the
nervous system, are diseases of the central nervous system. The main cause for the failure rate of
these drugs being higher than other areas of drug discovery is due to the blood-brain barrier. This
has become the major factor in limiting the production of drugs. The current medications used in
treating many of these diseases don’t treat the illness but relieve the symptoms.5
Scientists have found that drug repositioning has become really promising in overcoming
the barrier faced with full drug penetration through the blood-brain barrier. CNS drug
development must include three things: an understanding of the basic principles of the CNS
disease, the possibility of CNS side effects, the inability of the drug to penetrate the blood-brain
barrier. In general, the mechanisms of action of the many CNS diseases have been understood

for a while and that portion of the development of the drug does not get in the way.6 Our
understanding of these mechanisms continues to grow and change, but that doesn’t change the
drug development failure rate.
Another cause of CNS disease treatment failure is the drug side effects, which is often not
seen in the animal studies that are conducted to receive market approval.5 Some medications that
are used for the treatment of these CNS diseases, if used chronically, can lead to some serious
side effects. A common example is the use of NSAIDS that is used to treat chronic and
neuropathic pain, which is a side effect of some of these CNS diseases.6 Keeping the previous
reasons in mind, the main reason the treatment failure rate of these medications is so high is due
to the poor penetration efficacy across the BBB. About 100% of large-molecule drugs, including
peptides, recombinant proteins, monoclonal antibodies, RNAi-based drugs, and gene therapies
can’t cross the BBB. Greater than 98% of small-molecule drugs also don’t cross the BBB. This
leaves a very small portion of drugs, which explains the high failure rate in CNS drugs. 7
There is a great need to have a model that adequately models the BBB and drug
penetration in real humans when testing these drugs and their failure rates. An in vivo model is
the best at creating the environment that will give accurate results and the closest to what is
expected when this treatment is used in humans. There is one downside to using the in vivo
model. In vivo models utilize an entire animal, which can get expensive with extensive research.
The utilization of an in vitro model is the best option in this case. The in vitro model can create
an environment fairly like that of the in vivo model in just one petri dish. The benefits of using an
in vitro model outweigh the cons of using the model. Using an in vitro model is better pricewise
and requires less time compared to the in vivo model. In vitro models also offer the same

environment in numerous arrangements and get rid of the ethical questions that might raise with
the use of the in vivo model.7
There are a variety of in vitro models used to determine the penetration of the medication
through the BBB. Many of these models are commonly used in pharmaceutical research. Once
common model assay is Parallel Artificial Membrane Permeability Assays (PAMPA). PAMPA
was developed to determine passive transport permeability. The PAMPA consists of a filter plate
coated with a liquid artificial membrane. This is used to separate two compartments: one that
contains a buffer solution of compounds to be tested (donor compartment) and the other contains
an initial fresh buffer solution (acceptor compartment). 8 (Fig. 1)

Figure 1. Diagram of PAMPA model5

Another model commonly used to study BBB drug penetration is the cell culture inserts
with porous filter membranes. Researchers can choose from various cell culture inserts with
different pore diameters, pore densities, and membrane material. A benefit to using this model is
that using a cell culture insert makes it possible to divide the space into two domains. This can
mimic the blood (luminal) and brain (abluminal) side.9 The pore size and density of the
membrane can affect the permeability of the substrate. Apparent permeability (Papp) can be
calculated using this model.10 (Fig. 2) Specific cell culture devices with micro-holes have been
constructed for studying specifically BBB models.11

Figure 2. Cell Culture Inserts and Calculation of Permeability5

As mentioned earlier, drug repositioning has become a possibility for overcoming the
BBB and increasing drug penetration. Repositioning of already existing drugs has proven to be a
cost-effective and time-saving alternative. Drug repositioning uses the versatile properties of
already existing approved drugs to give them a new purpose. Drug repositioning has become a
very popular method in pharmaceutical research and has been used in other fields of drug
research.12 Drug repositioning publicly is referred to drugs that are approved for treatment of one

disease that can be used as a template for synthesis of derivatives that work against another
disease. Drug repurposing also exists which is the act of utilizing a certain drug that’s used to
treat a disease to treat another disease without any modification.13 A lot of times, the discoveries
made with drug repositioning are completely unintentionally. There are a lot of medications
commonly used that are used now for their drug repositioning effects, an example being
sildenafil.14 There have even been some instances that drug repositioning has helped with the
treatment of some CNS diseases, such as Parkinson’s Disease with the use of amantadine. (Table
1) Therefore, drug repositioning is a very promising field when it comes to CNS disease drug
discovery and many physicians and pharmacists can find these simply through patient
interaction.15

Drug Name

New Indication

Original Indication

Thalidomide

Multiple myeloma

Sleep inducer

Amantadine

Parkinson’s disease

Influenza

Valproic acid

Migraine

Epilepsy

Drug Name

New Indication

Original Indication

Zonisamide

Parkinson’s disease

Epilepsy

Daburafenib

Parkinson’s disease

Melanoma

Edaravone

Amyotrophic lateral sclerosis

Stroke

Topiramate

Obesity

Epilepsy

Table 1. Successful Drug Repositioning Examples5

In vitro BBB models can be effective tools in mimicking clinical settings and can help
advance the pharmaceutical study of various drugs used to treat CNS diseases. Using drug
repositioning with the models can be a cost-effective and time-saving approach to finding more
treatments for CNS diseases. (Fig. 3) It can also help reduce the failure rate of CNS treatment
drugs due to low drug penetration of the BBB.5

Figure 3. Comparison of Traditional Drug Discovery vs. Drug Repositioning Using In Vitro BBB
Model5

Consideration of Specific Test Subjects:
When a drug is in the process of research, it must go through various clinical trials, which
include gathering a group of people based off a specific criterion and testing the treatment on
them. When a patient receives a new medication, it is important that both the patient and the
physician/pharmacist understand how this medication will affect the person after taken. It’s hard
to determine this if many drug trials don’t have minority groups. The Human Genome Project
was an effort to determine the DNA sequence of the entire human genome. This was an
international effort because everyone has a different DNA sequence. Depending on the region,
ethnicity, race, etc. of someone, their DNA sequence can differ from someone on the other side
of the world.16 Therefore, it’s very important to put minorities in consideration when it comes to

drug clinical trials. It will help complete our overall understanding of how the drug works and its
effects.

Nervous System Disorders
There are many nervous system disorders, especially many of the central nervous system
(CNS). Before looking into the details of each disease and how the nervous system is affected,
it’s important that one understands the basic of the nervous system and the pathways used for
signaling by our neurons. This makes the picture clearer when illustrating the affects each of
these diseases has on the normal functioning of the nervous system.

Structure and Function:
The nervous system is responsible for communication between all parts of the body. It’s
also responsible for reacting to changes that occur both outside and inside the body. These
messages are sent and received through electrical and chemical means. 17
The building block of the nervous system is a nerve cell, or neuron. Neurons are
responsible for sending and receiving signals. The structure of a neuron can vary depending on
its location and purpose. All neurons do have two portions in common: dendrites, which are
projections and an axon, which is a long fiber. In many instances, the neuron is coated in a
membrane called the myelin sheath. The axon feathers out at the bottom into what are known as
axon terminals. (Fig. 4) These axon terminals encounter the dendrites of another neuron, and this
is where the communication occurs. The space between the axon terminals and dendrites is
known as the synapse. Messages from one neuron bounce to another through this synapse with
the help of chemicals known as neurotransmitters. (Fig. 5) What differentiates neurons from

other types of cells in the body is that they cannot be easily replaced if they die or are damaged
due to an infection or injury.17

Figure 4. Diagram of Structure of a Neuron18

Figure 5. Diagram of Synapse19

The nervous system can be branched into two parts, the central nervous system (CNS)
and the peripheral nervous system (PNS). (Fig. 6) The central nervous system is made up of the
brain and spinal cord and wrapped in meninges and cerebrospinal fluid (CSF). The brain is
where majority of the connections occur, and for sure the main connections take place there. The
brain oversees bodily functions, and it is also responsible for giving us personality, emotions,
consciousness, memory, etc. The spinal cord is connected to the brain and reaches all parts of the
body through nerves that branch of into the arms, legs, and torso. Nerves connect the peripheral
nervous system to the central nervous system. The PNS is made up to two parts: the autonomic
and the somatic nervous systems. One of the autonomic nervous system’s roles is to regulate
glands and organs. The autonomic nervous system is further separated into two parts: the
sympathetic and the parasympathetic. They act in opposite ways but cooperate to adjust when
our bodies go through a change. The somatic nervous system’s biggest role is to relay messages
from other parts of the body to the CNS. It’s also responsible for taking commands from the
CNS and making muscles relax or contract, allowing us to move.17

Figure 6. Central and Peripheral Nervous System Overview 20

The basal ganglia is the term used to refer to a group of structures in the brain that are
linked to the thalamus and that are involved in the coordination of movement of the body. There
are two distinct pathways that process signals and control movement: the direct and the indirect
pathway. The direct pathway facilitates certain motor movements, while the indirect pathway
limits this movement. Our brain must have a healthy balance of these to keep each pathway in
check. The direct pathway excites the motor cortex, which results in an increase of movement.
(Fig. 7) The indirect pathway inhibits the motor cortex, which decreases movement. When this

balance gets out of order, this results in various diseases, Parkinson’s disease being an
example.21

Figure 7. Diagram of Direct Pathway21

Figure 8. Diagram of Indirect Pathway21

There are three types of receptors that play a key role in the indirect and direct pathways:
glutamate receptors, GABA receptors and dopamine receptors. The glutamate receptors are
excitatory, and the GABA receptors are inhibitory. The dopamine receptors receive signals from
dopaminergic neurons. Both pathways are like a cycle and worked based off signals for
movement. The direct pathway is responsible for the excitation of the motor cortex, which is
responsible for sending signals to muscles in the body for movement, in turn, increasing
movement. The parts of the brain that play a role in the direct pathway are the motor cortex, the
striatum, the globus pallidus internal, the thalamus, the substantia nigra, and the subthalamic
nucleus. In the direct pathway, dopamine neurons synapse with GABA neurons in the striatum
on D1 receptors. A lack of these D1 receptors results in less inhibition of the globus pallidus. If

the globus pallidus isn’t inhibited, then the thalamus can’t be inhibited by the globus pallidus.
This results in decreased movement since the thalamus is not controlled and inhibited by the
globus pallidus.
In the indirect pathway, the main parts of the brain are the motor cortex, thalamus,
striatum, substantia nigra, subthalamic nucleus, and globus pallidus external. The purpose of the
indirect pathway is to reduce unwanted movements. The dopamine neurons synapse with the D2
receptors on the glutamate neurons of the striatum. A lack of dopamine receptors leads to
increased movement through this pathway. This is a result of the striatum inhibiting the globus
pallidus too much and not allowing the thalamus to send excitatory signals to the motor cortex. 22

Disorders:
Parkinson’s Disease

I.

Parkinson’s disease (PD) is a neurodegenerative disorder, resulting in the loss of dopamine
neurons located in the substantia nigra of the brain. Patients with Parkinson’s disease experience
both motor and nonmotor symptoms, although specialists focus more on the motor symptoms
since those are the ones that are more evident and found in every patient. Some of the motor
symptoms of Parkinson’s disease include tremors, loss of balance, and bradykinesia, which is
slowness of movement.
There are several factors that play a role in the likeliness of someone developing PD.
Research has shown that these influences can be genetic, environmental, or based on other
biochemical factors. A specific genetic mutation has been identified as a mutation that eventually
leads to the development of PD. This mutation can be passed on through generations and is not
as common as environmental or biochemical factors. Environmental factors can also lead to PD,

such as the use of illicit drugs or exposure to the metal manganese. The most common cause of
PD is biochemical factors, specifically the loss of dopamine in the substantia niagra (SNc). This
loss leads to the loss of communication to the thalamus, globus pallidus, and subthalamic nucleus
(STN), leading to many of the motor symptoms commonly found with PD. All these factors have
shown to result in the loss of these dopaminergic neurons, leading to the onset of PD. 23
Parkinson’s disease doesn’t have any medications or treatments that we could use to stop the
neurodegeneration of these dopamine neurons. Since these are also neurons, once they are lost
and die off, these neurons won’t ever regenerate like other cells in the body can. All these
medications and treatments used currently by specialists are to help suppress the symptoms these
patients experience. One method that specialists have found to be useful for patients is the use of
the drug Carbidopa-Levodopa.24 Levodopa is known to be the amino acid precursor of dopamine.
When taken, the levodopa is converted into dopamine and crosses the blood-brain barrier, a
specialized barrier to keep many substances out of the brain. This replaces the loss of dopamine
in patients with PD, making it a very valuable treatment option.25 Carbidopa is a decarboxylase
inhibitor that works to prevent levodopa from being broken down before it reaches the brain.26
(Fig. 9) Doctors have been giving Carbidopa-levodopa is commonly given orally, but doctors
have also given it as an inhalation and infusion.
Another medication that is used by physicians as treatment for PD is dopamine agonists.
These agonists don’t transform into dopamine like Carbidopa-levodopa does, they just mimic the
same effects. They aren’t as effective as levodopa but is known to last longer. Dopamine
agonists include pramipexole (Mirapex), ropinirole (Requip), rotigotine (Neupro), and
apomorphine (Apokyn).27 They bind to the dopamine receptors and activate the signaling
pathway.28 MAO B inhibitors include selegiline (Zelapar), rasagiline (Azilect), and safinamide

(Xadago) and are also another form of medication used. They help prevent the breakdown of
dopamine by inhibiting the enzyme monoamine oxidase B (MAO B). (Fig. 9) Catechol Omethyltransferase (COMT) inhibitors, such as entacapone (Comtan) and opicapone (Ongentys)
are also used as treatment. This type of medication slightly prolongs the effect of levodopa
therapy by blocking the enzyme that breaks down dopamine. (Fig. 9) Anticholinergics have been
used to treat a common side effect of PD, tremors. Some of these medications include
benztropine (Cogentin) and trihexyphenidyl.27 Anticholinergic medications are antagonists of the
neurotransmitter acetylcholine, which is the primary transmitter of nerve impulses within the
parasympathetic nervous system. This effect the contraction of muscles, which is why it's a
helpful medication for controlling tremors.29 Amantadine is also commonly prescribed by
physicians to treat side effects of early-stage PD and is sometimes given along with carbidopalevodopa during the later stages of PD.27 Amantadine is a weak antagonist of the NMDA
receptor, leading to an increase in dopamine release and prevents dopamine reuptake.30

Figure 9. Mechanism of Action of Common Drugs Used to Treat PD 31

II.

Depression
Depression, also known as major depressive disorder, is a common and serious illness that

affects how you feel, the way you think, and how you act. Depression can cause feelings of

sadness and a loss of interest in activities that were once enjoyed. It can lead to various
emotional and physical problems and can impede with the ability of functioning at work and
home. Some symptoms can include: feeling sad, loss of interest, change in appetite, change in
sleeping habits, loss of energy, feeling worthless, difficulty thinking and concentrating, and
thoughts of death and suicide. For someone to be diagnosed with depression, these symptoms
must last longer than two weeks and must be different than your previous level of functioning.
Depression is estimated to affect one in 15 adults and one in six people will experience a
depressive episode once in their lifetime. Often people are diagnosed in their late teens to mid20s. Women have shown to be more likely to experience depression compared to men. There is
also a high chance of genetics affecting diagnosis, since about 40% of people that have a firstdegree relative with depression are likely to be diagnosed with depression. There are several risk
factors that play a role in depression. There are biochemistry factors that are cause by differences
in certain chemicals in the brain that can lead to symptoms of depression. Personality also plays
a role where people with low self-esteem and who are easily overwhelmed and pessimistic.
Environmental factors also play a role. People that have continuous exposure to violence,
neglect, and abuse are more likely to experience depression.32
There are several types of classes of antidepressants that are used to treat depression.
Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed medications. Some
common ones include: sertraline (Zoloft), paroxetine (Paxil), fluoxetine (Prozac), and citalopram
(Celexa).33 SSRIs increase the levels of serotonin in the brain. Serotonin is one of the
neurotransmitters that carries signals between neurons. SSRIs block reuptake of serotonin into
neurons, which makes more serotonin available to improve communication between neurons. 34
(Fig. 10)

Figure 10. SSRI Mechanism of Action 35

Serotonin and noradrenaline reuptake inhibitors (SNRIs) are also used to treat depression and
long-term anxiety. Some common drugs include venlafaxine (Effexor), desvenlafaxine (Pristiq),
and duloxetine (Cymbalta).33 SNRIs block the reabsorption of serotonin and norepinephrine, a
stress hormone and neurotransmitter, in the brain.36 (Fig. 11) Tricyclic antidepressants are
another class of antidepressants and were the first class of antidepressants approved for
treatment. Common medications include nortriptyline (Pamelor), amitriptyline (Elavil), and

imipramine (Tofranil).33 (Fig. 12) Tricyclic antidepressants block the reuptake of serotonin and
norepinephrine. They also act on approximately four other different neurotransmitter pathways to
achieve the right effects.37 Norepinephrine and dopamine reuptake inhibitors are also commonly
used to treat depression, including seasonal affective disorder. The only medication in this class
is bupropion (Wellbutrin). Wellbutrin has many “off label” uses including anxiety, bipolar
disorder, and ADHD.33 (Fig. 13)

Figure 11. SNRI Mechanism of Action38

III.

ADHD
Attention-Deficit/ Hyperactivity Disorder (ADHD) is a very common neurodevelopmental

disorder in children. This disorder is usually first diagnosed in childhood and often can last
through adulthood. Children with this disorder often have trouble paying attention, controlling
impulsive behaviors, or being overly active. Symptoms include forgetting things, squirming,
talking too much, making careless mistakes, etc. There are three different types of ADHD,

depending on which symptoms are strongest in the individual. The first type is predominantly
inattentive presentation. The signs of this presentation are trouble organizing, paying attention,
and a person being easily distracted. The second type is known as predominantly hyperactiveimpulsive presentation. The signs presented with this are fidgeting, restlessness, impulsivity, and
talking a lot. There is also combined presentation where they show signs of both.39
There aren’t definitive causes and risk factors for ADHD. Recent studies have shown that
genetics can play an important role in ADHD diagnosis.40 Other possible causes and risk factors
that scientists have been studying include brain injury, exposure to certain environmental risks,
premature delivery, and more.39 There are three classes of drugs commonly used to treat ADHD.
Stimulants are the most used drug class and work for about 70% to 80% of people. It is used to
treat moderate to severe ADHD. Common medications include Adderall, Focalin, Ritalin,
Vyvanse, and Concerta.41 Each of these stimulants has a slightly different mechanism of action,
but in general the mechanism revolves around increased catecholamine levels and increased
agonistic activity and adrenergic receptors.42 (Fig. 12)

Figure 12. Stimulant Mechanism of Action 43

Non-stimulant ADHD medications are commonly used when someone sees adverse effects
from the use of stimulants. Common medications used include atomoxetine (Strattera), clonidine,
guanfacine, and viloxazine (Qelbree).41 Atomoxetine’s mechanism of action is a norepinephrine
reuptake inhibitor. It has a high affinity and selectivity for norepinephrine transporter, all this
inhibition occurring in the prefrontal cortex.44 Clonidine acts as an agonist. It has an alphaagonist effect in the posterior hypothalamus and medulla. This leads to reduced sympathetic
outflow from the CNS. Clonidine can also be used to lower blood pressure, due to its agonistic

features.45 Guanfacine is known to stimulate postsynaptic alfa-2A adrenergic receptors,
inhibiting the production of cAMP. It also closes HCN channels, enhancing the effectiveness of
the signal of the prefrontal cortex neurons. This leads to improvement in working memory and
attention.46 Viloxazine’s mechanism of action is unique compared to the other medications used
to treat ADHD. Most of the ADHD medications used are norepinephrine reuptake inhibitors
(NRI). Viloxazine is a serotonin-norepinephrine modulating agent (SNMA). Viloxazine
modulates 5-HT receptors in the CNS, these receptors have an influence on things such as mood,
cognition, memory, perception, emotion, and consciousness. Therefore, Viloxazine has been
used as a neuropsychiatric medication to treat disorders such as ADHD and depression. 47 There
are some off-label antidepressants that doctors also use to treat ADHD, since many patients also
experience symptoms of depression. Some of these include bupropion and nortriptyline.41 (Fig.
13)

Figure 13. NRI and SNMA Mechanism of Action 47

IV.

Bipolar Disorder
Bipolar disorder (manic depression) is known for causing unusual changes is someone’s
mood, energy, concentration, and activity levels throughout the day. Bipolar disorder is typically
categorized into three different types. Every type still has symptoms of changes in mood, energy,
and activity levels. The range of periods of “highs” and “lows” is what differentiates the three
types of this disorder. The first type is known as Bipolar I Disorder. This type normally exhibits
manic episodes that last at least 7 days, sometimes having manic behaviors that require medical
attention. Along with the manic episodes, depressive episodes can also occur and typically last at
least two weeks. These episodes can alternate or can also occur simultaneously. The second type
is known as Bipolar II Disorder. This type is expressed through a pattern of depressive and
hypomanic episodes, but they are not as full-blown as Bipolar I Disorder. The third type is
known as Cyclothymic Disorder, which is defined by periods of hypomanic symptoms and
periods of depressive symptoms that last for at least two years. These symptoms don’t reach
requirements to be categorized as hypomanic or depressive episodes, though. Occasionally there
will be a patient that experiences bipolar disorder symptoms, but they can’t be categorized into
one of the three types. This is known as “other specified and unspecified bipolar and related
disorders”. Typically, bipolar disorder is diagnosed during late teen years or early adulthood.
Sometimes children can also experience these symptoms. Bipolar disorder usually requires
lifelong treatment, which can help improve the quality of life of the patients.48
There isn’t one single cause of bipolar disorder and researchers believe that several risk
factors can contribute to the diagnosis. One factor could be the structure and functioning of the
brain. Some studies have shown that the brains of people with bipolar disorder differ from those

without bipolar disorder. Even though this could be a contributing factor, physicians typically
diagnose bipolar disorder based on a person’s symptoms and their history. Genetics could also be
a risk factor for developing bipolar disorder. Like other neuropsychiatric illnesses, research has
suggested that there are some genes that increase the likeliness of developing bipolar disorder.
Research also suggests that having a direct family member with bipolar disorder can also
increase a person’s chance of developing the illness. When diagnosing this disorder, physician
typically investigate the person’s symptoms, environmental factors around them, and their family
history to determine their diagnosis and what could have triggered it.48
Physicians typically prescribe medication to improve the person’s quality of life and
improve their symptoms. One type of medication that physicians prescribe is a mood stabilizer to
control the person’s manic episodes. Some examples include lithium (Lithobid), valproic acid
(Depakene), divalproex sodium (Depakote), carbamazepine (Tegretol), and lamotrigine
(Lamictal).49 Many of these mood stabilizers have different mechanisms of action. These
mechanisms include modulation of GABA-ergic and glutamatergic neurotransmission and
alteration of voltage-gated ion channels or intracellular signaling pathways.50 (Fig. 14 and 15)

Figure 14. Lithium Mechanism of Action 51

Figure 15. Lamotrigine Mechanism of Action52

Another medication commonly used to treat bipolar disorder is antipsychotics. Normally
these are added to the treatment plan if symptoms persist despite treatment with other
medications. Some examples include olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole,
(Abilify), lurasidone (Latuda), and asenapine (Saphris).49 There are two different types of
antipsychotics commonly used in pharmacology. The first-generation inhibit dopaminergic
neurotransmission. Second-generation antipsychotics block D2 dopamine receptors and
serotonin receptor antagonist action.53 Physicians may also prescribe antidepressants to help
manage someone’s depressive episodes. The medication Symbyax has also become a common
treatment since it combines the effects of fluoxetine and olanzapine. It is also known as an
antidepressant-antipsychotic medication.49 Symbyax is known for activating the serotonin,

norepinephrine, and dopamine pathways, which gives it it’s antidepressant properties. He
combination of fluoxetine and olanzapine have shown to increase norepinephrine, dopamine, and
serotonin release in the prefrontal cortex compared to each drug on its own.54 Occasionally
physcians may prescribe benzodiazepines, which are anti-anxiety meds. These are typically used
on a short-term basis and are used to improve sleep and help with anxiety.49 Common drug
names include diazepam (Valium), oxazepam (Serax), lorazepam (Ativan), alprazolam (Xanax),
and clonazepam (Klonopin).55 Benzodiazepines are positive allosteric modualtars on GABA-A
receptors. GABA receptors are inhibitory, which leads to a calming effect of the brain and less
exciatability of the neurons. Benzodiazepines bind to certain subunits of GABA-A receptors and
induce a conformational change. This results in hyperpolarization of the cell and GABA’s
inhibitory effects throughout the CNS.56 (Fig. 16)

Figure 16. GABA Receptor with Target Sites56

Accessibility of Drugs
The many neurological disorders above affect the lives of many people and anyone could
be at risking for developing these illnesses. It’s important that we understand the way these
disorders can affect people’s lives and how to better treat them. But even with that, it can be easy
for some minority groups to be overlooked in the research conducted on these illnesses. Every
human body is different and the reaction to certain medications can vary. It is important that
minority groups are put in as a part of these research studies that are conducted to be able to
better treat society. Patients can be marginalized based on their biological sex, Sexual orientation
(gender identification), socioeconomic class, and race. Marginalization, especially in drug
development, can lead to improper treatment and, in some cases, hesitation on both the patient
and physician’s end to initiate treatment.
The FDA Office of Women’s Health and the Society for Women’s Health Research
(SWHR) have recently worked together to increase the discussion of diversifying clinical trials.
Research has shown that women have 1.5-1.7-fold greater risk of developing an adverse drug
reaction. Physical discrepancies between men and women also have created gender-bias when it
comes to the use of medical devices for treatment. The FDA and SWHR teamed up to come up
with a few strategies for more diversity in clinical trials. The first step was to recruit more female
and minority physicians to manage clinical trials. Research has shown that minorities, in general,
are more drawn to seek a physician with similar background. This will be a motivating factor for
all minorities to join various clinical trials. Due to various events of exploitation in medical
research, minorities are hesitant in participating. Transparent communication can create trust and
get rid of any hesitation, according to the FDA and SWHR’s recommendations. Many times,

minorities are hesitant in joining these trials to lack of awareness or involvement in the
community on the research team’s behalf. Increasing awareness and involving communities in
the research may lead to more trust, therefore less hesitation from minorities, including
females.57

Biological Sex:
Biological sex has been a barrier for many for ages and it continues in many ways
nowadays. Typically, women have struggled throughout history to get their voices heard and to
become a part of many important conversations. We’ve seen this with many events in history,
such as the ratification of the 19th amendment and the many waves of feminism in the past few
decades. Before the 19th and 20th centuries, women were typically associated with the illness
known as “hysteria”. Hysteria is the first mental disorder that was attributed to women. Hysteria
is first described as having symptoms of mania or depressive episodes. The cause was believed
to be spontaneous uterus movements. It later came to be found in the contemporary age that
males could also have episodes of hysteria. This marginalization of women in the discussion of
mental health for centuries has led to further discussions nowadays on including women in
mental health research and digging deeper into the idea of gender-specific mental health issues
and that can affect women.58
Researchers conducted an observational study on Medicare beneficiaries with PD in
2002. Results showed that along with minorities, women were also less likely to receive
specialist care compared to their white men counterparts. Getting neurologist care as a patient
with PD could lead to improved clinical outcomes and greater survival.63 There were also higher

rates of boys getting proper ADHD diagnosis with adequate treatment compared to their female
counterparts.57

Sexual Orientation (Gender Identification):
Sexual and gender minority (SGM) is a common term used to describe the overall
LGBTQ+ community and is inclusive to all sexual and gender orientations/identification. People
of this community experience higher levels of mental health disorders due to the minority stress
theory. The minority stress theory consists of social stressors on minority groups, especially seen
in SGM, stigma, prejudice, and discrimination due to their status in society. This is major cause
of increased rates of mental health disorders in SGM communities compared to other
communities of majority status.58 Studies have shown that sexual minority women are less likely
to receive a physical examination and dental examination compared to their majority
counterparts. This puts them at risk of not getting adequate treatment. Sexual minority women
were significantly more likely to rate their health status as fair or poor compared to their
counterparts, making them more susceptible to being diagnosed with illnesses like depression,
anxiety, and ADHD. Sexual minority men were also more likely to be diagnosed with these
illnesses and getting treatment, like sexual minority women. 59
Recent studies have shown that sexual minority women (SMW) are more likely to
experience mental health problems like depression and anxiety. This could be due to minority
stress that is added on top of other stress. SMW can experience stress through victimization,
internalized homophobia, and concealment of their sexual orientation. They also have less access
to some psychosocial resources and social support due to the stigma surrounding their sexual
orientation, which can also lead to health disparities. SMW seek out treatment programs more

than their heterosexual counterparts. One study found that nearly three times as many SMW
reported dissatisfaction with their mental health services compared to their heterosexual
counterparts.60 In general, women and men from sexual minority groups had more unmet
treatment needs of mental disorders, compared to their heterosexual counterparts.61

Socioeconomic Class:
According to various research conducted over the years, low socioeconomic position
(SEP) makes a person more suspectable and puts them at a higher risk of developing various
mental health illnesses. Common mental health illnesses that are seen include schizophrenia,
depression, anxiety disorders, and bipolar disorders. Also, according to the World Mental health
surveys put out by the World Health Organization (WHO), there is a higher stigma that comes
with low SEP, and they have a different perceived position in society. Findings showed that there
was a higher level of mental disorders among those people that with low perceived social status
due to low SEP.62
Medicaid data from 9 states between the years 2008-2011 gives us insight on the
discrepancies of treatment of children with ADHD due to socioeconomic class. Children that
were receiving ADHD treatment through the Medicaid program available in their state, were
more likely to not receive satisfactory treatment and the overall care quality is poor. Only threefifths received follow-up care and under two-fifths received combined treatment. Due to the lack
of adequate psychotherapy, there is a higher occurrence of treatment disengagement due to
higher rates of medication discontinuation.63 People with lower socioeconomic class are less
likely to insurance coverage, making treatment less accessible. Diagnosis and treatment of
ADHD is affected by socioeconomic classes and race/ethnicity.64

Race:
PD is more prominent in Caucasian men than any other group. This suggests that there
could be a genetic influence on PD, like mentioned above. Studies have shown that there was a
small amount of randomized clinical trials (RCTs) that reported race or ethnicity when
evaluating treatment of symptoms of PD.65 Demographic and clinical characteristics were
examined in a tertiary-care center to determine if there were any discrepancies. Through the
investigation, they noticed a difference in medication use between the white majority and the
minority group. Non-Caucasians tended to be more on anticholinergics and Caucasians tended to
be more on levodopa therapy. This could suggest that this difference could be due to suggestions
of therapies and/or response disparities.66
Studies analyzed in the United Kingdom (UK) with data from studies conducted in the
United States (US), suggest that there are disparities in diagnosis, treatment, and survival of PD
in ethnic minorities compared to white patients. Ethnic minorities with PD were less likely to
receive dopamine replacing therapy or any pharmacological treatment. Similarly, there were
ethnic disparities in chronic pain management in PD patients. Researchers in the UK conducted
their own study and found that ethnic disparities also exist in chronic management of PD patients
in the UK from their sample of participants from London.67 (Fig. 17)

Figure 17. Proportion of Patients Receiving Pain Medication Based on Ethnic Group 67

Research has shown that there are also disparities in treatment availability and mental
health care, specifically relating to depression. Researchers found that there was a significant
difference between the care African Americans and non-Latino whites received. African
Americans had lower odds of receiving adequate depression care compared with whites. NonLatino whites with depression were predicted to have access to adequate depression treatment
compared to multiple groups of minorities. The percentage of non-Latino whites having access to
treatment was 33.4% compared to 25.0% of Latinos, 18.9% of Asians, and 10.4% of African
Americans.68 (Fig. 18) Several studies have also shown that physicians tend to provide different
types of treatment or quality of treatment across different ethnic/racial minorities. One study
conducted in east London documented that the prescription rates for antidepressants varied
throughout the area of the city and were the lowest in the areas that the highest proportions of

Asian immigrants. A report released by the Institute of Medicine states that, even though there
aren’t clear factors determining these discrepancies, they could be a result from clinician bias,
stereotyping, and uncertainty in clinical decision making and communication.69

Figure 18. Data Comparing Depression Treatment Access68

Comparison:
In general, minority groups, whether it be based on race/ethnicity, sex, socioeconomic
status, or sexual orientation, there are treatment discrepancies in the treatment of various nervous
system disorders, ranging from movement disorders such as PD to mental health disorders such
as depression. Research was conducted on novel therapeutics that were approved by the FDA
between 2011 and 2013 to determine the representation of minorities in the clinical studies,

specifically focusing on age, biological sex, and race. The results indicated that women were
equally represented in the clinical trials, but there was great discrepancy in the race of the
participants, with majority being white. (Table 2) Before approval, the FDA did perform
subgroup analyses by age, sex, and race.70 African-Americans and other racial/ethnic minorities
were also shown to be undertreated or treated inappropriately and be given limited access to
mental health services and optimal treatment for bipolar disorder.71

Table 2.70

Race/Ethnicity

Percentage (mean)

White

79.2%

Black

7.4%

Asian

7.4%

Other

5.9%

Hispanic

13.3%*

*only available for 59.8% of indications

Discussion
Treatment of these various disorders is important to prevent these diseases becoming
more severe and effecting the quality of life of the patient. When treating a patient, many factors
must be considered to give adequate care and treatment. A big factor is considering the patient’s
background and determining if they come from any minority groups. Research has shown that
collaborative care can be very beneficial in treating depression. This can include specific
culturally/linguistic tailoring to improve communication between the patient and physician to
improve treatment options.73

Studies have shown that health care professionals involved in the treatment of these
patients don’t have diverse backgrounds. Although the number of professionals with minority
race/ethnic backgrounds has slightly increased between the years 1999-2006, this doesn’t seem
to be enough to accurately improve treatment of minority group patients. Having a more diverse
workforce can lead to an increase in race/ethnic minority patient involvement in clinical trials
and an increase in adequate treatment of these minority groups.74
According to Michael Losow, a lawyer in the field, medicine has become personalized
nowadays, which makes it even more important to focus on minority groups when considering
treatment. Losow believes that it is necessary to study these minority groups specifically in the
process of drug development, since it is known that medication can affect every person
differently.75 There are many factors that should play a role in drug development and later
treatment of patients. It is important that minority groups are accounted for in these various
clinical trials and later receiving treatment. Many factors affect the diagnosis of these nervous
system disorders, many including genetics and environmental factors. Research has shown that
minority groups are more susceptible to these risk factors. Changing the way minority groups are
faced and treated could in some cases make the difference between life and death. Focusing on
these groups could help health care professionals better understand their backgrounds and find
new and improved ways to access of adequate treatment.

Appendix
Glossary:
Acetylcholine: chief neurotransmitter of the parasympathetic nervous system
Anticholinergic: inhibition of the physiological action of acetylcholine as a neurotransmitter

Axon: the long threadlike part of a nerve cell along which nerve impulses are conducted from
the cell body to other cells
Axon Terminals: small swellings that are found at the terminal ends of axons where synapses
are typically found
Basal Ganglia: a group of structures linked to the thalamus in the base of the brain and involved
in coordination of movement
Blood-brain barrier: a filtering mechanism of the capillaries that carry blood to the brain and
spinal cord tissue, blocking the passage of certain substances
Bradykinesia: a principal symptom of Parkinson’s Disease that is characterized by slowness of
movement
Central Nervous System: part of nervous system consisting of the brain and spinal cord
Dendrite: a short, branched extension of a nerve cell, along which impulses received from other
cells at synapses are transmitted to the cell body
In vitro: in a test tube, culture dish, or elsewhere outside a living organism
In vivo: in a living organism
Motor Cortex: the part of the cerebral cortex in the brain where the nerve impulses originate
that initiate voluntary muscular activity
Myelin Sheath: an insulating layer made up of protein and fatty substances that forms around
nerves allowing electrical impulses to transmit quickly and efficiently along nerve cells
Neurotransmitter: a chemical substance released at the end of a nerve fiber by the arrival of a
nerve impulse and, by diffusing across the synapse or junction, causes the transfer of the impulse
to another nerve fiber, muscle fiber, or some other structure

Noradrenaline/Norepinephrine: a hormone released by adrenal medulla and sympathetic
nerves and functions as a neurotransmitter
Peripheral Nervous System: part of nervous system that consists of all peripheral nerves
Subthalamic Nucleus: an oval-shaped structure located ventrally to the thalamus in the brain
that plays a fundamental role in the circuitry of the basal ganglia and its nerves
Substantia Nigra: a layer of deeply pigmented gray matter situated in the midbrain and
containing the cell bodies of a tract of dopamine-producing nerve cells
Synapse: the site of transmission of electric nerve impulses between two neurons or between a
neuron and a gland or muscle cell
Thalamus: a mostly gray matter structure in the third ventricle of the brain that is composed of
different nuclei that each serve a unique role, ranging from relaying sensory and motor signals,
as well as regulation of consciousness and alertness
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